<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>About 10-15% of patients with acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AAA) have resistant/<z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression </plain></SENT>
<SENT sid="1" pm="."><plain>We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> and post-transfusion HCV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept </plain></SENT>
<SENT sid="3" pm="."><plain>Over a 12 months follow-up he experienced only transient increase of liver transaminases </plain></SENT>
</text></document>